The ARSA Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human hepatic adenocarcinoma SK-HEP-1 cell line via targeted disruption of the ARSA gene. This product provides a heterogeneous mixture of cells harboring diverse CRISPR-induced loss-of-function mutations, suitable for bulk population studies without clonal selection. The polyclonal format preserves genetic diversity and facilitates experiments where population-level phenotypes are of primary interest. The knockout model is designed for researchers investigating lysosomal enzyme function, sphingolipid metabolism, and related disease mechanisms.
The parental SK-HEP-1 cell line is an ascites-derived human liver adenocarcinoma model, originally established from a patient with hepatic adenocarcinoma. This adherent epithelial line is widely used in cancer biology, drug metabolism, and liver pathophysiology studies. SK-HEP-1 cells retain key hepatic features, including expression of certain liver-specific markers, yet exhibit a transformed phenotype suitable for oncological and metabolic investigations. Their robust growth and compatibility with standard cell culture techniques make them a versatile host for gene editing, introducing a lysosomal defect in a cancer context.
ARSA encodes arylsulfatase A, a lysosomal enzyme essential for sulfatide desulfation to galactocerebroside in the sphingolipid catabolism pathway. It functions in concert with the cofactor saposin B (PSAP), which presents sulfatide to the enzyme. ARSA expression is transcriptionally regulated by the MiT/TFE family members TFEB, MITF, and TFE3, master controllers of lysosomal biogenesis. CRISPR-mediated ARSA disruption abolishes enzymatic activity, leading to lysosomal sulfatide accumulation that recapitulates the metabolic hallmark of metachromatic leukodystrophy (MLD). This model enables dissection of MLD pathology and lysosomal sphingolipid handling in a liver cancer background.
Knocking out ARSA in SK-HEP-1 cells merges lysosomal storage pathology with hepatic adenocarcinoma, providing a unique platform to study how sulfatide accumulation influences cancer cell biology, metabolism, and stress responses. Given the liver’s central role in lipid metabolism, this model is particularly relevant for investigating hepatic contributions to sphingolipid dysregulation in MLD and for evaluating therapeutic strategies targeting lysosomal dysfunction in cancer. The polyclonal nature ensures representation of diverse knockout genotypes, potentially reflecting patient heterogeneity.
These cells are ideally suited for MLD disease modeling, sulfatide metabolism studies, and drug screening for small molecules or gene therapies aimed at restoring ARSA function. Typical applications involve western blotting to confirm ARSA loss, ARSA enzyme activity assays, sulfatide lipidomics, immunofluorescence for lysosomal markers (e.g., LAMP1), lysosomal pH measurements, and cell viability assays under lysosomal stress. The product also supports cancer metabolism research and investigations into MiT/TFE transcription factor networks. For further technical information or customized support, please contact Ascent Research.
